Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensus.
Authors:
- Joseph M BrandweinJBJoseph M Brandwein
- Michelle GeddesMGMichelle Geddes
- Jeannine KassisJKJeannine Kassis
- Andrea K KewAKAndrea K Kew
- Brian LeberBLBrian Leber
- Thomas NevillTNThomas Nevill
- Mitchell SabloffMSMitchell Sabloff
- Irwindeep SandhuISIrwindeep Sandhu
- Andre C SchuhASAndre C Schuh
- John M StorringJSJohn M Storring
- John AshkenasJAJohn Ashkenas
- 5 May 2013
- journal article
- Vol. 3 (2) , 141-64
Abstract
Patients over age 60 comprise the majority of those diagnosed with acute myeloid leukemia (AML), but treatment approaches in this population are variable, with many uncertainties and controversies. Our group conducted a literature review to summarize the latest information and to develop a consensus document with practical treatment recommendations. We addressed five key questions: selection criteria for patients to receive intensive induction chemotherapy; optimal induction and post-remission regimens; allogeneic hematopoietic stem cell transplantation (HSCT); treatment of patients not suitable for induction chemotherapy; and treatment of patients with prior hematological disorders or therapy-related AML. Relevant literature was identified through a PubMed search of publications from 1991 to 2012. Key findings included the recognition that cytogenetics and molecular markers are major biologic determinants of treatment outcomes in the older population, both during induction therapy and following HSCT. Although disease-specific and patient-specific risk factors for poor outcomes are more common in the older population, age is not in itself sufficient grounds for withholding established treatments, including induction and consolidation chemotherapy. The role of HSCT and use of hypomethylating agents are discussed. Finally, suggested treatment algorithms are outlined, based on these recommendations.Keywords
This publication has 100 references indexed in Scilit:
- Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: results of the prospective AML96 trialLeukemia, 2010
- Reduced Mortality after Allogeneic Hematopoietic-Cell TransplantationNew England Journal of Medicine, 2010
- Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosisCancer, 2010
- Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid LeukemiaJournal of Clinical Oncology, 2010
- Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: Hematologic Malignancy Outcomes Are Not Impaired in Advanced AgeTransplantation and Cellular Therapy, 2010
- IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B StudyJournal of Clinical Oncology, 2010
- Randomized trial of two schedules of low‐dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML‐19)British Journal of Haematology, 2010
- Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology GroupBritish Journal of Haematology, 2009
- Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trialBritish Journal of Haematology, 2006
- A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemiaBlood, 2006